Exenatide for Myocardial Protection During Reperfusion Study

Exclusion Criteria

• •Symptomatic hypoglycemia (serum glucose \<3.3 µmol/L; 60 mg/dl)
• •Diabetes mellitus requiring insulin therapy
• •Diabetic ketoacidosis
• •Coronary anatomy warranting emergent coronary artery bypass graft surgery
• •Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation)
• •Need for hemodialysis
• •Malignancy, HIV, or central nervous system disorder
• •Cardiopulmonary resuscitation \>15 min and compromised level of consciousness.
• •Cardiogenic shock
• •Current participation in any research study involving investigational drugs or devices
• •Inability to give informed consent
• •Inability to safely undergo cMRI (presence of cardiac pacemaker, implanted cardiac defibrillator, aneurysm clips, carotid artery vascular clamp, neurostimulator, implanted drug infusion device, bone growth/fusion stimulator, cochlear, otologic, or ear implant, severe claustrophobia)
• •Women of childbearing potential who are known to be pregnant or lactating or who have a positive pregnancy test on admission
• •History of pancreatitis
• •Known end stage renal failure or known eGFR \<30 mL/min
• •Currently taking exenatide (Byetta, Bydureon), liraglutide (Victoza), or any other GLP-1 agonist